Rivermark Medical Completes Enrollment in Pivotal Study for the FloStent™ System

Rivermark Medical's Latest Milestones



Rivermark Medical, known for its innovative approaches to treating benign prostatic hyperplasia (BPH), proudly announced the completion of patient enrollment in its pivotal RAPID III clinical study regarding the FloStent™ System. This achievement marks a significant step forward in the company's journey to provide effective treatments for men suffering from BPH, a condition affecting nearly 40 million men in the United States alone.

About the RAPID III Study



The RAPID III study is a multicenter, randomized, double-blind trial evaluating the safety and effectiveness of the FloStent™ for men experiencing lower urinary tract symptoms due to BPH. A total of 216 participants were randomized in this study, with the primary goal of assessing changes in the International Prostate Symptom Score (IPSS).

Adam Kadlec, M.D., co-founder and CEO of Rivermark Medical, expressed gratitude towards the patients, investigators, and clinical teams involved in making the enrollment a success. “Completing enrollment in RAPID III is an important milestone for Rivermark,” Kadlec remarked, emphasizing the significance of their efforts during the study's details and execution.

The Innovative FloStent™ System



The FloStent™ is designed as a minimally invasive implant, with the goal of alleviating urinary symptoms associated with BPH without making alterations to the surrounding tissue. Its unique integration with standard flexible cystoscopes allows for placement in a routine outpatient setting, avoiding the need for additional capital equipment. Moreover, adjustments or retrieval of the device can be done using standard urological tools, preserving other treatment options for the future.

Leadership Enhancements



In tandem with their clinical advancements, Rivermark Medical has bolstered its leadership team by appointing two prominent figures in the medical device field. Steve Blum, a seasoned urology industry veteran, has joined Rivermark's Board of Directors. Blum previously held key positions at Coloplast, leading various divisions including Men’s Health and Endosurgery. His deep expertise in urology will be invaluable as Rivermark plans its next stages of growth.

Additionally, Raymond W. Cohen, a co-founder of Axonics and former CEO, has been named Senior Advisor to Rivermark. With over four decades in the life sciences sector, Cohen brings a wealth of knowledge in navigating corporate landscapes and preparing for commercial launches. He expressed confidence in Rivermark's direction as it gears up for its Premarket Approval (PMA) submission to the U.S. Food and Drug Administration.

The Broader Impact of BPH



Despite not being life-threatening, BPH significantly impacts the quality of life for millions of men worldwide. Existing treatment options often come with trade-offs regarding efficacy, invasiveness, and recovery times. Rivermark Medical's focus on patient-friendly, minimally invasive solutions reflects a commitment to enhancing the treatment landscape for BPH.

This commitment is intrinsic to the company's mission, which is articulated through its founder Adam Kadlec's clinical insights, ensuring real-world needs are addressed through innovative technologies.

For further updates on Rivermark Medical and its pioneering endeavors with the FloStent™, interested parties can visit their official website at Rivermark Medical.

Conclusion



The completion of enrollment in the RAPID III study, combined with strategic leadership appointments, positions Rivermark Medical as a key player in the urology field. With continual follow-up and data collection ongoing, the company is on a promising path toward significant advancements in the management and treatment of BPH. By catering to both patient choice and the operational needs of physicians, Rivermark is poised to bridge critical gaps in current treatment frameworks for BPH.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.